Table 1—

Baseline clinical and biochemical characteristics of 7,209 Chinese type 2 diabetic patients with no history of stroke divided according to the development of first stroke during a median follow-up of 5.37 years

NonstrokeStrokeP value
n6,837372
Male sex45.448.10.3132*
Smoking status
    Current smoker20.025.50.0098*
    Ex-smoker13.519.40.0015*
Retinopathy25.640.6<0.0001*
Sensory neuropathy25.042.5<0.0001*
Peripheral vascular disease5.412.6<0.0001*
History of CHD5.512.1<0.0001*
Age (years)56 (20)68 (12)<0.0001
BMI (kg/m2)24.7 (4.9)24.6 (4.5)0.3892
Waist circumference (men) (cm)88.0 (12.0)88.0 (9.5)0.6016
Waist circumference (women) (cm)83.0 (13.0)84.8 (11.5)0.0103
Years of diagnosed diabetes5 (9)9.0 (12.0)<0.0001
SBP (mmHg)133 (27)144 (30)<0.0001
DBP (mmHg)76 (14)77 (14)0.1360
A1C (%)7.3 (2.0)7.8 (2.5)<0.0001
Spot urine ACR (mg/mmol)1.88 (9.24)9.59 (60.8)<0.0001
eGFR (ml/min per 1.73 m2)85.6 (34.7)72.0 (34.0)<0.0001
LDL-to-HDL cholesterol ratio2.47 (1.31)2.73 (1.49)0.0004
Non-HDL cholesterol (mmol/l)3.86 (1.40)3.97 (1.48)0.0158
Total-to-HDL cholesterol ratio4.08 (1.73)4.37 (1.88)0.0017
Triglyceride (mmol/l)1.38 (1.10)1.40 (1.10)0.6065
On diet treatment at baseline10.15.70.0047*
Use of oral antidiabetes drugs at baseline61.158.60.3402*
Use of antihypertensive drugs at baseline other than ACEI/ARB34.246.0<0.0001*
Use of insulin at baseline17.524.7<0.0004*
Use of LLDs at baseline13.712.60.5478*
Use of ACEI or ARB at baseline20.523.90.1081*
Use of aspirin at baseline8.514.20.0011*
  • Data are percent or median (interquartile range) unless otherwise indicated. eGFR was from the glomerular filtration rate from the modified Modification of Diet in Renal Disease formula.

  • *

    * Derived from χ2 test.

  • Derived from Wilcoxon two-sample test.

  • Data for 1,271 patients (stroke events = 82) who enrolled before 1 December 1996 were not available. ACEI, ACE inhibitor; DBP, diastolic blood pressure; LLD, lipid-lowering drug.